A team at Texas Children's Duncan Neurological Research Institute and Baylor College of Medicine has offered an answer to a long-standing puzzle in neurodegeneration: why a harmful protein found throughout the brain and body destroys only a few specific regions. Writing in Genes & Development, the researchers report that the partner proteins that bind a disease protein differ from tissue to tissue - both in the forms they take and in how much of them is present - and those differences produce distinct molecular interactions and distinct biological consequences.
The work centered on spinocerebellar ataxia type 1, or SCA1, studied in animal models. As Dr. Huda Zoghbi, the study's corresponding author and Duncan NRI's founding director, describes it, SCA1 is a rare neurodegenerative disorder marked by progressive loss of coordination, slurred speech and difficulty swallowing, all stemming from damage to the cerebellum, the brain region governing coordination and balance. The culprit is a mutation in the ATAXIN-1 gene, which yields an overly active protein that builds up inside cells and injures them.
That gene is switched on in many brain regions and in organs including the heart and liver, yet the cerebellum and brain stem bear the brunt of the damage. The new findings suggest the local protein partners are what tip the balance, making some tissues vulnerable while others tolerate the same faulty protein. Practically, that reframes the therapeutic target: rather than blunting the disease protein everywhere, treatments aimed at specific protein forms could act where the damage actually happens.
The researchers note the principle is not limited to SCA1 and could apply to other neurological conditions in which a widely expressed protein causes narrowly focused harm - a description that fits much of the neurodegeneration field, including more common dementias. For now the evidence comes from animal models, and translating a tissue-specific targeting strategy into human therapy remains the next step.